Programmed cell death protein 1 (PD-1) and cytotoxic T lymphocyte antigen-4 (CTLA-4) blockade therapy are effective for treating patients with different mismatch repair metastatic CRC (6, 7). The gene discussed is PDCD1; the disease is colorectal carcinoma.